
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Results of epidemiological studies presented at theannual meeting of the Society for Investigative Dermatology do not supporta causal relationship between isotretinoin use and treatment for depression.






